A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia |
| |
| Authors: | Yu-Hung Wang Chi-Yuan Yao Chien-Chin Lin Kristian Gurashi Fabio M. R. Amaral Hasse Bossenbroek Andres Jerez Tim C. P. Somervaille Moritz Binder Mrinal M. Patnaik Hsin-An Hou Wen-Chien Chou Kiran Batta Daniel H. Wiseman Hwei-Fang Tien |
| |
| Affiliation: | 1. Division of Cancer Sciences, The University of Manchester, Manchester, UK;2. Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan;3. Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, Manchester, UK;4. Haematology Department, Hospital Morales Meseguer, Murcia, Spain;5. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA |
| |
| Abstract: | Leukaemic stem cell (LSC) gene expression has recently been linked to prognosis in patients with acute myeloid leukaemia (17-gene LSC score, LSC-17) and myelodysplastic syndromes. Although chronic myelomonocytic leukaemia (CMML) is regarded as a stem cell disorder, the clinical and biological impact of LSCs on CMML patients remains elusive. Making use of multiple independent validation cohorts, we here describe a concise three-gene expression signature (LSC-3, derived from the LSC-17 score) as an independent and robust prognostic factor for leukaemia-free and overall survival in CMML. We propose that LSC-3 could be used to supplement existing risk stratification systems, to improve prognostic performance and guide management decisions. |
| |
| Keywords: | chronic myelomonocytic leukaemia leukaemia stem cell prognostic scoring system |
|
|
